Thermo Fisher Scientific Yönetim

Yönetim kriter kontrolleri 3/4

Thermo Fisher Scientific CEO'su Marc Casper, Oct2009 tarihinde atandı, in görev süresi 15.08 yıldır. in toplam yıllık tazminatı $ 18.98M olup, şirket hissesi ve opsiyonları dahil olmak üzere 9.1% maaş ve 90.9% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.046% ine doğrudan sahiptir ve bu hisseler € 91.01M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 5 yıl ve 12.7 yıldır.

Anahtar bilgiler

Marc Casper

İcra Kurulu Başkanı

US$19.0m

Toplam tazminat

CEO maaş yüzdesi	9.1%
CEO görev süresi	15.1yrs
CEO sahipliği	0.05%
Yönetim ortalama görev süresi	5yrs
Yönetim Kurulu ortalama görev süresi	12.7yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Marc Casper'un ücretlendirmesi Thermo Fisher Scientific'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 28 2024	n/a	n/a	US$6b
Jun 29 2024	n/a	n/a	US$6b
Mar 30 2024	n/a	n/a	US$6b
Dec 31 2023	US$19m	US$2m	US$6b
Sep 30 2023	n/a	n/a	US$6b
Jul 01 2023	n/a	n/a	US$6b
Apr 01 2023	n/a	n/a	US$6b
Dec 31 2022	US$28m	US$2m	US$7b
Oct 01 2022	n/a	n/a	US$7b
Jul 02 2022	n/a	n/a	US$7b
Apr 02 2022	n/a	n/a	US$8b
Dec 31 2021	US$21m	US$2m	US$8b
Oct 02 2021	n/a	n/a	US$9b
Jul 03 2021	n/a	n/a	US$9b
Apr 03 2021	n/a	n/a	US$8b
Dec 31 2020	US$26m	US$2m	US$6b
Sep 26 2020	n/a	n/a	US$5b
Jun 27 2020	n/a	n/a	US$4b
Mar 28 2020	n/a	n/a	US$4b
Dec 31 2019	US$19m	US$2m	US$4b
Sep 28 2019	n/a	n/a	US$4b
Jun 29 2019	n/a	n/a	US$4b
Mar 30 2019	n/a	n/a	US$3b
Dec 31 2018	US$19m	US$1m	US$3b
Sep 29 2018	n/a	n/a	US$3b
Jun 30 2018	n/a	n/a	US$2b
Mar 31 2018	n/a	n/a	US$2b
Dec 31 2017	US$22m	US$1m	US$2b

Tazminat ve Piyasa: Marc 'nin toplam tazminatı ($USD 18.98M ), Austrian pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 4.34M ).

Tazminat ve Kazançlar: Marc 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Marc Casper (56 yo)

15.1yrs

Görev süresi

US$18,976,669

Tazminat

Mr. Marc N. Casper has been the Chief Executive Officer and President of Thermo Fisher Scientific, Inc. since October 15, 2009 and has been its Chairman of the Board of Directors since February 26, 2020. M...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Marc Casper	Chairman	15.1yrs	US$18.98m	0.046% € 91.0m
Stephen Williamson	Senior VP & CFO	9.3yrs	US$6.24m	0.010% € 20.7m
Michel Lagarde	Executive VP & COO	2.8yrs	US$7.25m	0.0044% € 8.8m
Lisa Britt	Chief Human Resources Officer & Senior VP	7.7yrs	US$2.89m	0.0035% € 6.9m
Gianluca Pettiti	Executive Vice President	no data	US$5.73m	0.0044% € 8.6m
Joseph Holmes	VP & Chief Accounting Officer	3.7yrs	Veri yok	0.00041% € 812.9k
Ryan Snyder	Senior VP & Chief Information Officer	5.3yrs	Veri yok	Veri yok
Karen Nelson	Chief Scientific Officer	3.3yrs	Veri yok	Veri yok
Rafael Tejada	Vice President of Investor Relations	no data	Veri yok	Veri yok
Michael Boxer	Senior VP & General Counsel	6.8yrs	US$3.12m	0.0032% € 6.3m
Sandy Pound	VP & Chief Communications Officer	4.1yrs	Veri yok	Veri yok
Paul Parker	Senior Vice President of Strategy & Corporate Development	4.6yrs	Veri yok	Veri yok

5.0yrs

Ortalama Görev Süresi

56yo

Ortalama Yaş

Deneyimli Yönetim: TMOF 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 5 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Marc Casper	Chairman	15.1yrs	US$18.98m	0.046% € 91.0m
Scott Sperling	Independent Lead Director	18yrs	US$403.12k	0.019% € 37.4m
C. Harris	Independent Director & Member of Scientific Advisory Board	12.7yrs	US$325.72k	0.0022% € 4.4m
Nelson Chai	Independent Director	13.9yrs	US$365.72k	0.0037% € 7.4m
Lars Sorensen	Independent Director	8.5yrs	US$345.72k	0.0024% € 4.8m
Mark Stevenson	Member of Scientific Advisory Board	no data	US$9.40m	Veri yok
Tyler Jacks	Member of Scientific Advisory Board & Director	15.5yrs	US$345.72k	0.0022% € 4.4m
Cynthia Wolberger	Member of Scientific Advisory Board	7yrs	Veri yok	Veri yok
William Hahn	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Debora Spar	Independent Director	5.2yrs	US$345.72k	0.00040% € 793.1k
Steven Gygi	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Dion Weisler	Independent Director	7.7yrs	US$353.19k	0.0012% € 2.3m

12.7yrs

Ortalama Görev Süresi

61yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: TMOF 'in yönetim kurulu deneyimli ve tecrübelidir (ortalama görev süresi 12.7 yıldır).

Thermo Fisher Scientific Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

Insider recently sold €2.0m worth of stock

Thermo Fisher Scientific Inc., Annual General Meeting, May 22, 2024

Thermo Fisher Scientific Appoints Srinath Venkatesh as Managing Director, India and South Asia

Thermo Fisher Scientific Inc. Appoints Jennifer “Jenny” Johnson to the Audit Committee

Thermo Fisher Scientific Inc. Elects Jenny Johnson to Board of Directors

Recent updates

Thermo Fisher Scientific Inc. Declares Quarterly Cash Dividend, Payable on January 15, 2025

Third quarter 2024 earnings released: EPS: US$4.27 (vs US$4.44 in 3Q 2023)

Thermo Fisher Scientific Inc. Provides Earnings Guidance for the Year 2024

Thermo Fisher Scientific Introduces Fully Integrated Multimodal Analytical Scanning Transmission Electron Microscope to Advance Novel Research in Materials Science

Thermo Fisher Scientific Introduces Mass Spectrometers to Simplify Trace Elemental Analysis and Enhance Productivity

Thermo Fisher Scientific Inc. to Report Q3, 2024 Results on Oct 23, 2024

Now 20% undervalued

Upcoming dividend of US$0.39 per share

FDA Grants Thermo Fisher Scientific Inc.'s SeCore HLA Typing Kit 510(k) Clearance for Use as Companion Diagnostic with a T-Cell Receptor Therapy for Synovial Sarcoma

Now 21% undervalued

Thermo Fisher Scientific Inc. Announces Extended 510k Clearance of Freelite Assays for Evaluation of MGUS

Insider recently sold €2.0m worth of stock

Thermo Fisher Scientific Inc. Showcases Diagnostics Innovation Across Therapeutic Areas at ADLM 2024

Second quarter 2024 earnings released: EPS: US$4.05 (vs US$3.53 in 2Q 2023)

Thermo Fisher Scientific Inc. Raises Earnings Guidance for the Year 2024

First quarter dividend of US$0.39 announced

Thermo Fisher Scientific to Help Advance Myeloid Cancer Clinical Research and Treatment Utilizing Next Generation Sequencing Technology

Thermo Fisher Scientific Inc. (NYSE:TMO) completed the acquisition of Olink Holding AB (publ) (NasdaqGM:OLK) from Summa Equity AB and others.

Thermo Fisher Scientific Inc. to Report Q2, 2024 Results on Jul 24, 2024

Thermo Fisher Scientific Inc.(NYSE:TMO) dropped from Russell 1000 Growth-Defensive Index

Thermo Fisher Scientific Introduces the Only Fully Automated Plasmid Purification System to Help Accelerate Discovery and Development of Therapies

Thermo Fisher Scientific Introduces Thermo Scientific Heracell VIOS 250i AxD CO2 Incubators

Upcoming dividend of US$0.39 per share

Thermo Fisher Scientific Introduces Innovative Mass Spectrometer to Advance Clinical Research

Thermo Fisher Scientific Updates Chromosomal Microarray Analysis Solutions to Comply with IVDR Regulation

First quarter dividend of US$0.39 announced

Thermo Fisher Scientific Inc. Declares Quarterly Dividend, Payable on July 15, 2024

Thermo Fisher Scientific Introduces Array-Based Solution for Extended Blood Type Research to Support Future Advancements Toward Safer Transfusions

First quarter 2024 earnings released: EPS: US$3.48 (vs US$3.34 in 1Q 2023)

Thermo Fisher Scientific Inc. Raises Revenue Guidance for the Full Year 2024

Thermo Fisher Scientific Inc. Introduces Animal Origin-Free Formulation to Support Scaling of Cell Therapy Manufacturing

Thermo Fisher Scientific Inc., Annual General Meeting, May 22, 2024

Thermo Fisher Scientific Introduces Its Newest Line of High Performance, Ultra-Low Temperature (ULT) Freezers

Thermo Fisher Scientific Inc. to Report Q1, 2024 Results on Apr 24, 2024

Thermo Fisher Scientific Announces A New In-Line Metrology Solution to Improve Battery Safety and Performance

Thermo Fisher Scientific Inc. Launches Corevitas Clinical Registry in Generalized Pustular Psoriasis

Upcoming dividend of US$0.39 per share

Fourth quarter dividend of US$0.39 announced

Full year 2023 earnings released: EPS: US$15.53 (vs US$17.73 in FY 2022)

Thermo Fisher Scientific Inc. Increases Quarterly Cash Dividend, Payable on April 15, 2024

Now 20% undervalued

Thermo Fisher Scientific Inc. Launches New Ion Chromatography Instrument to Improve Reliability, Efficiency, and Functional Adaptability for Labs

Thermo Fisher Scientific Expands GMP Laboratory Service Offerings with Biosafety Testing Including Mycoplasma Testing

Full year 2023 earnings released: EPS: US$15.53 (vs US$17.73 in FY 2022)

Now 21% undervalued

Thermo Fisher Scientific Inc. Announces Earnings Guidance for Full Year 2024

Thermo Fisher Scientific Appoints Srinath Venkatesh as Managing Director, India and South Asia

Thermo Fisher Scientific Receives GMP Approval from the Italian Medicines Agency for its Manufacturing Facility of RNA-Based Products in Monza, Italy

Thermo Fisher Scientific Inc. Announces Launch of Innovative Corevitas Pharmacovigilance Platform for Clinical Research Registries

Thermo Fisher Scientific Inc. Announces the Launch of the Thermo Scientific KingFisher Apex Dx and Applied Biosystems MagMAX Dx Viral/Pathogen NA Isolation Kit

Upcoming dividend of US$0.35 per share at 0.3% yield

Thermo Fisher Scientific Declares Quarterly Dividend, Payable on January 16, 202

Thermo Fisher Scientific Announces New Fault Localization Solution for the Analysis of Advanced Logic Semiconductors

Third quarter 2023 earnings released: EPS: US$4.44 (vs US$3.81 in 3Q 2022)

Thermo Fisher Scientific Inc. Provides Earnings Guidance for the Year 2023

Thermo Fisher Scientific Inc. (NYSE:TMO) proposed an offer to acquire Olink Holding AB (publ) (NasdaqGM:OLK) from Summa Equity AB and others for approximately $3.3 billion.

Thermo Fisher Scientific Inc. (NYSE:TMO) proposed an offer to acquire Olink Holding AB (publ) (NasdaqGM:OLK) from Summa Equity AB and others for approximately $3.3 billion.

Thermo Fisher Scientific Inc. to Report Q3, 2023 Results on Oct 25, 2023

Thermo Fisher Scientific Inc. Appoints Jennifer “Jenny” Johnson to the Audit Committee

Thermo Fisher Scientific Helps Accelerate Cell Therapy Manufacturing with A Next-Generation Platform of Gibco™ CTS™ Detachable Dynabeads™

Upcoming dividend of US$0.35 per share at 0.3% yield

Thermo Fisher Scientific Announces the Launch of the EXENT Solution with IVDR Certification

Thermo Fisher Scientific Introduces New Chromosomal Microarray with Two-Day Turnaround Time to Increase Lab Productivity

Thermo Fisher Scientific Inc. (NYSE:TMO) acquired CorEvitas, LLC from Audax Management Company, LLC for approximately $910 million.

Thermo Fisher Scientific Announces a New Line of Thermo Scientific TM TSG Series Refrigerators

Thermo Fisher Scientific Inc. Revises earnings Guidance for 2023

Second quarter 2023 earnings released: EPS: US$3.53 (vs US$4.25 in 2Q 2022)

Thermo Fisher Scientific Introduces New Reproductive Health Assays to Accelerate Fertility Research

Thermo Fisher Scientific Inc. Elects Jenny Johnson to Board of Directors

Thermo Fisher Scientific Inc. (NYSE:TMO) has entered into a definitive agreement to acquire CorEvitas, LLC from Audax Management Company, LLC for Approximately $910 million.